Table 4.

Characteristics of responding patients. CR: complete remission; PR: partial remission; MR: minor response; SD: stable disease; M: male; F: female; LMS: leiomyosarcoma; S: sarcoma; GIST: gastrointestinal stromacell sarcoma; ASPS: alveolar soft part sarcoma; ST: soft tissue; Abd: abdominal; L: lung/pleura; Li: liver; Ret: retroperitoneal; P: peritoneal; LN: lymph nodes; Th: thyroid; K: kidney; B: bone; br: brain.

Best response	Patients number (%)	Sex	Age (years)	Histology	Disease sites	Number of previous lines	Anthracycline resistance (a)	Bulky (b)	Response duration (months)
CR	1 (1.1)	M	57	Liposarcoma	ST, Abd	1	N	N	8.7 +
PR	5 (5.6)	F	71	LMS	L	1	Y	N	43.5
		F	61	Osteosarcoma	L	2	N	N	15
		M	46	Myogenic	Li, LN, ST	2	N	N	11
		F	38	LMS uterus	Li, L, ST, P	1	Y	N	7.3
		M	41	Liposarcoma	Ret, P	0	—	Y	2.7 +
MR	1 (1.1)	F	76	Synovial S	L	1	N	N	5.8
SD ≥ 6 months	16 (17.9)	F	37	GIST	Abd	0	—	N	43.5
		F	56	LMS	LN, ST, L, B	2	N	Y	19.3 +
		M	35	LMS	L	2	N	N	12.5
		M	61	LMS	Li, B	1	Y	N	11
		M	76	LMS	L, Li, ST, K	1	N	Y	7
		F	42	LMS	L, Li, ST	1	N	N	7
		F	60	LMS uterus	ST	2	Y	N	6.8
		F	31	Liposarcoma	Th, Abd	2	N	Y	12.2
		F	58	Liposarcoma	Abd	1	Y	Y	8.5 +
		M	58	Liposarcoma	Abd	2	N	Y	8
		M	53	Liposarcoma	Retr, K	3	N	Y	8 +
		F	40	Synovial S	LN, ST, Li, P	1	N	N	7
		M	21	Synovial S	L, LN	1	Y	N	6.8
		M	46	Spindle cell S	L, B, skin	2	Y	N	17 +
		M	29	ASPS	L	1	N	N	13.5
		F	3	Osteosarcoma	B, ST, br	2	Y	N	9

^(a)Anthracycline resistance: progression occurring while under anthracycline-containing treatment, within 3 months of completing palliative treatment or within 6 months of completing adjuvant treatment with anthracyclines.

^(b)Bulky disease: existence of at least one tumor mass with a diameter of at least 10 cm.

⁺: Patients still undergoing treatment with ET-743, disease progression not yet reached.